Xiao, F. ., Xiao, W. ., Li, X., Li, R. ., & Zhao, K. . (2024). Cost-effectiveness analysis of Trastuzumab Deruxtecan as second-line treatment for HER2- positive advanced breast cancer. Health Decision, 2(S1). https://doi.org/10.54844/hd.2024.0009